



## (51) International Patent Classification:

A61P 35/00 (2006.01) C07D 417/14 (2006.01)

## (21) International Application Number:

PCT/EP2023/084669

## (22) International Filing Date:

07 December 2023 (07.12.2023)

## (25) Filing Language:

English

## (26) Publication Language:

English

## (30) Priority Data:

63/386,709 09 December 2022 (09.12.2022) US  
63/515,641 26 July 2023 (26.07.2023) US

(71) Applicants: **GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.4) LIMITED** [GB/GB]; GSK Medicines Research Centre, Gunnels Wood Road, Stevenage SG1 2NY (GB). **IDEAYA BIOSCIENCES, INC.** [US/US]; 7000 Shoreline Court, Suite 350, South San Francisco, California 94080 (US).

(72) Inventors: **BOTYANSZKI, Janos**; GSK, 1250 South Collegeville Road, Collegeville, Pennsylvania 19426 (US). **DUFFY, Kevin**; GSK, 1250 South Collegeville Road, Collegeville, Pennsylvania 19426 (US). **NEILAN, Claire L.**; IDEAYA BIOSCIENCES, INC., 7000 Shoreline Court, Suite 350, South San Francisco, California 94080 (US). **FISCHER, Marcus Michael**; IDEAYA BIOSCIENCES, INC., 7000 Shoreline Court, Suite 350, South San Francisco, California 94080 (US). **CHOI, Young Eun**; GSK, 200 Cambridge Park Drive 6th Floor, Cambridge, Massachusetts 02140 (US).

(74) Agent: **GLADWIN, Amanda et al.**; GSK, 980 Great West Road, Brentford Middlesex TW8 9GS (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,


MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

## Published:

- with international search report (Art. 21(3))
- in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE

(54) Title: THIADIAZOLYL DERIVATIVES AS DNA POLYMERASE THETA INHIBITORS AND USES THEREOF



(57) Abstract: Disclosed herein are compounds of Formula (I) that inhibit DNA Polymerase Theta (Polθ) activity, in particular inhibit Polθ activity by inhibiting ATP dependent helicase domain activity of Polθ. Also, disclosed are pharmaceutical compositions comprising such compounds and methods of treating and/or preventing diseases treatable by inhibition of Polθ such as cancer, including homologous recombination (HR) deficient cancers.